240 related articles for article (PubMed ID: 35368052)
1. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Nissen SE; Wolski K; Balog C; Swerdlow DI; Scrimgeour AC; Rambaran C; Wilson RJ; Boyce M; Ray KK; Cho L; Watts GF; Koren M; Turner T; Stroes ES; Melgaard C; Campion GV
JAMA; 2022 May; 327(17):1679-1687. PubMed ID: 35368052
[TBL] [Abstract][Full Text] [Related]
2. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial.
Nissen SE; Wolski K; Watts GF; Koren MJ; Fok H; Nicholls SJ; Rider DA; Cho L; Romano S; Melgaard C; Rambaran C
JAMA; 2024 May; 331(18):1534-1543. PubMed ID: 38587822
[TBL] [Abstract][Full Text] [Related]
3. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.
Nissen SE; Linnebjerg H; Shen X; Wolski K; Ma X; Lim S; Michael LF; Ruotolo G; Gribble G; Navar AM; Nicholls SJ
JAMA; 2023 Dec; 330(21):2075-2083. PubMed ID: 37952254
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
5. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Tsimikas S; Viney NJ; Hughes SG; Singleton W; Graham MJ; Baker BF; Burkey JL; Yang Q; Marcovina SM; Geary RS; Crooke RM; Witztum JL
Lancet; 2015 Oct; 386(10002):1472-83. PubMed ID: 26210642
[TBL] [Abstract][Full Text] [Related]
6. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.
Nicholls SJ; Nissen SE; Fleming C; Urva S; Suico J; Berg PH; Linnebjerg H; Ruotolo G; Turner PK; Michael LF
JAMA; 2023 Sep; 330(11):1042-1053. PubMed ID: 37638695
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
Rider DA; Eisermann M; Löffler K; Aleku M; Swerdlow DI; Dames S; Hauptmann J; Morrison E; Lindholm MW; Schubert S; Campion G
Atherosclerosis; 2022 May; 349():240-247. PubMed ID: 35400495
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
9. Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a).
Kosmas CE; Bousvarou MD; Papakonstantinou EJ; Tsamoulis D; Koulopoulos A; Echavarria Uceta R; Guzman E; Rallidis LS
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686428
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease.
Rider D; Chivers S; Aretz J; Eisermann M; Löffler K; Hauptmann J; Morrison E; Campion G
Toxicol Sci; 2022 Sep; 189(2):237-249. PubMed ID: 35737426
[TBL] [Abstract][Full Text] [Related]
11. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
13. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects.
Thomas T; Zhou H; Karmally W; Ramakrishnan R; Holleran S; Liu Y; Jumes P; Wagner JA; Hubbard B; Previs SF; Roddy T; Johnson-Levonas AO; Gutstein DE; Marcovina SM; Rader DJ; Ginsberg HN; Millar JS; Reyes-Soffer G
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1770-1775. PubMed ID: 28729361
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).
Koren MJ; Moriarty PM; Baum SJ; Neutel J; Hernandez-Illas M; Weintraub HS; Florio M; Kassahun H; Melquist S; Varrieur T; Haldar SM; Sohn W; Wang H; Elliott-Davey M; Rock BM; Pei T; Homann O; Hellawell J; Watts GF
Nat Med; 2022 Jan; 28(1):96-103. PubMed ID: 35027752
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study.
Sohn W; Winkle P; Neutel J; Wu Y; Jabari F; Terrio C; Varrieur T; Wang J; Hellawell J
Clin Ther; 2022 Sep; 44(9):1237-1247. PubMed ID: 35963802
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP
JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410
[TBL] [Abstract][Full Text] [Related]
20. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)
Marcovina SM; Viney NJ; Hughes SG; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(1):122-129.e2. PubMed ID: 29174389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
